Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
Beijing University First Hospital, Beijing, Beijing, China
Ambulance Amsterdam, Amsterdam, Netherlands
Sir Run Run Hospital, Nanjing, Jiangsu, China
Beijing Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Southern medical university Nanfang hospital, Guangzhou, China
Women's hospital, school of medicine, Zhejiang university, Hangzhou, Zhejiang, China
Peking University First Hospital, Beijin, Bejing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.